Printer Friendly

MATRIX PHARMACEUTICAL RECEIVES APPROVALS FOR HUMAN CLINICAL TRIALS IN CANCER

             MATRIX PHARMACEUTICAL RECEIVES APPROVALS FOR
                    HUMAN CLINICAL TRIALS IN CANCER
    MENLO PARK, Calif., Nov. 18 /PRNewswire/ -- Matrix Pharmaceutical, Inc. today announced the approval of two Investigational New Drug (IND) applications from the Food and Drug Administration (FDA) to begin Phase I/II clinical trials for the treatment of life-threatening cancers including head and neck cancer and prostate cancer.  Nine clinical studies will be conducted at major U.S. cancer treatment centers.
    The IND's cover Matrix's anti-cancer drugs, MPI 5011 and MPI 5004, which are site-specific, sustained-release, injectable therapeutics containing proven anti-cancer drugs, protein carriers and vasoconstrictors.  In the company's proprietary approach to treatment, compounds are delivered directly to diseased tissues and held in place by protein carriers.  This approach concentrates drug activity at the site and reduces side effects that are often associated with systemic administration.
    "We are pleased with the IND approvals for our anti-cancer therapeutics and expect that they will further our efforts in the treatment of skin disorders and cancer," said Craig R. McMullen, chief executive officer of Matrix.  "In the new trials, we look forward to demonstrating that the treatment of life-threatening cancers is one of many promising applications for our proprietary site-specific products."
    The newly approved IND protocols provide for the use of MPI 5011 in the treatment of such cancers as prostate cancer and liver cancer. Indications for MPI 5004 will include head and neck cancer and prostate cancer.
    Matrix Pharmaceutical, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of proprietary site-specific therapeutics for cancer and skin diseases.  To date, the company has a total of four drugs in human clinical studies.  Based in Menlo Park, Calif., Matrix Pharmaceutical was incorporated in 1985 and currently has 35 employees.
    -0-          11/18/91
    /CONTACT:  Beverly Holley of Matrix Pharmaceutical, 415-326-6100; or Karen Bergman of Burns McClellan, 212-545-1919, for Matrix Pharmaceutical/ CO:  Matrix Pharmaceutical Inc. ST:  California IN:  MTC SU: FC-SH -- NY012 -- 1237 11/18/91 08:54 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1991
Words:328
Previous Article:THIRD-QUARTER RESULTS FOR JACOBSON STORES INC.
Next Article:TOYS
Topics:


Related Articles
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
SCICLONE PHARMACEUTICALS ANNOUNCES APPROVAL TO BEGIN CLINICAL TRIALS IN JAPAN FOR THYMOSIN ALPHA 1
National Cancer Institute Extends Collaboration with CollaGenex Pharmaceuticals, Inc.
NCI Files IND For First CollaGenex Cancer Drug
Agouron Initiates Pivotal Trials of Oral Anti-Angiogenesis Drug AG3340 for Treatment of Lung Cancer and Prostate Cancer
Matrix Pharmaceutical Licenses Anticancer Agent from Hoechst Marion Roussel.
Agouron Announces Confirmatory Trial of Oral Anti-Angiogenesis Drug Prinomastat for Treatment of Lung Cancer.
Novogen Anti-Cancer Drug Enters Phase I Clinical Trials.
Reportlinker Adds World Cancer Therapies Market Report.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters